AD-303 (topical dutasteride)
AD-303 (topical dutasteride) is in Phase 1/2 for androgenetic alopecia, developed by Moogene Medi.
A topical dutasteride from Korea, run alongside an oral form in one study to pick a dose for further development.
- Developed by
- Moogene Medi
- Current phase
- Phase 1/2
- Mechanism
- 5α-reductase inhibitor
- Indications
- Androgenetic alopecia
- Also known as
- AD-303, AD303, AD-303A, AD-3031
- Last public activity
- March 2026
- Copy last reviewed
- September 2026
- Record confidence
- Low
A combined safety and early-efficacy study.
Stops testosterone being converted into DHT, the hormone that drives pattern hair loss.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
Dutasteride inhibits both isoforms of 5-alpha-reductase where finasteride inhibits one, and is approved for hair loss in South Korea and Japan, as the dutasteride entry in this register records; a topical would be the same bet as topical finasteride, systemic exposure traded for a local effect. The registered study runs a topical arm (AD-303A) alongside an oral arm (AD-3031) in men, measuring pharmacokinetics, scalp DHT and safety to support dose selection, with a planned start in April 2026 and completion in December; the record has not been updated since March 2026. Moogene Medi is the sponsor of record, with Seoul National University Hospital as collaborator, and has not published what the formulation is.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
Moogene Medi Co., Ltd · n=30 · April 2026
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia — ClinicalTrials.gov
Related programmes
Other programmes in the register with the same mechanism: 5α-reductase inhibitor.
Cite this page
Hair Pipeline, "AD-303 (topical dutasteride) — development record", hairpipeline.com/pipeline/ad-303